Is Supernus Pharmaceuticals, Inc. (SUPN) Overvalued?
We dive into why Supernus Pharmaceuticals, Inc. (SUPN) could be considered overvalued on 2026-08-04, based on AAII’s Value Score and Grade.Jenna Brashear
Stock Evaluator: Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. SUPN
$42.78
0.78
1.86%
September 21, 2026 4:00:00 PM
EST
Volume: 635,719
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Commentary & Analysis
Why Supernus Pharmaceuticals, Inc.’s (SUPN) Stock Is Up 6.58%
As of Wednesday, August 05, Supernus Pharmaceuticals, Inc.’s SUPN share price has surged by 6.58%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Supernus Pharmaceuticals, Inc.’s (SUPN) Stock Is Up 8.46%
As of Monday, August 03, Supernus Pharmaceuticals, Inc.’s SUPN share price has surged by 8.46%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Supernus Pharmaceuticals, Inc.'s Q3 Earnings
Supernus Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Monday, August 03. Let's dive in to see if (SUPN) missed or beat analyst's expectations.Michael Rose
Which Is a Better Investment, Supernus Pharmaceuticals, Inc. or Trulieve Cannabis Corp. Stock?
Learn more about whether Supernus Pharmaceuticals, Inc. or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | SUPN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,486.7 | $584.0 | 57% |
|
| Shares Out (Mil) | 58.1 | 43.1 | 51% |
|
| Institutional Ownership | 95.8% | 83.7% | 68% |
|
| Float (Mil) | 51.7 | 45.1 | 47% |
|
| Beta | 0.56 | 0.72 | 32% |
|
| Avg Daily Volume (000s) | 694 | 336 | 62% |
|
| Price Change (52-week) |
(7.3%) | 64.2% | 44% |
|
| Growth | SUPN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.7% | 6.7% | 44% |
|
| Net Income (5yr) | (18.2%) | (1.4%) | 22% |
|
| EPS (5yr) | (18.0%) | 15.1% | 15 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (12.1%) | (15.0%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | $0.615 | $2.565 | $4.460 | |
| Month Ago EPS | $0.615 | $2.565 | $4.460 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.667 | $2.487 | $4.343 | |
| Year/Year Chg | (160.9%) | (475.5%) | (890.6%) | |
| Financials | SUPN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $830 | $317 | 48% |
|
| Net Income (TTM) (Mil) | ($110) | ($11) | 10% |
|
| EPS (TTM) | ($1.914) | ($0.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | $20 | ($6) | 41% |
|
| Net Cash Flow (TTM) (Mil) | $37 | $5 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $29 | $6 | 35% |
|
| Enterprise Value (Q1) (Mil) | $2,163 | $493 | 50% |
|
| Valuation | SUPN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.41 | 2.50 | 58% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SUPN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 72.9% | 69.4% | 83% |
|
| Net Margin | (13.2%) | 2.5% | 19% |
|
| ROA | (7.8%) | (22.4%) | 27% |
|
| ROE | (10.5%) | (21.8%) | 27% |
|
| Liabilities to Assets | 27.8% | 32.4% | 19% |
|
| F-Score | 4 | 3 | 33% |
|
Supernus Pharmaceuticals, Inc. did not pass any screens on 9/21/2026.
